Agenus to Participate in February Investor Conferences
26 Januar 2023 - 1:30PM
Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline
of immunological agents targeting cancer and infectious disease,
today announced that Dr. Garo Armen, Chairman and CEO, and Dr.
Steven O’Day, Chief Medical Officer, will participate in the
following upcoming investor conferences:
- Guggenheim
5th Annual Oncology Day
– Fireside chat presentation will be held in-person on Thursday,
February 9th, 2023 at 9:35 AM ET
- SVB Securities Global
Biopharma Conference – Fireside chat presentation will be
held virtually on Thursday, February 16th, 2023 at 10:00 AM ET
A live webcast of the presentations from Guggenheim and SVB
Securities conferences can be accessed on the company’s website at
https://investor.agenusbio.com/events-and-presentations. A replay
will be posted following the event.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
ContactAgenus Inc.Zack ArmenHead of Investor
Relations917-362-1370zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024